Pα+ Psychedelic Bulletin #227: A Closer Look at Compass’ 6-Month Data; AtaiBeckley Deal Update; ‘Rysanso’ Brand MDMA?
- A Closer Look at Compass’ 6-Month Data and Commercial Plans
- Will Branded MDMA Go By ‘Rysanso’?
- Sources Say AtaiBeckley Deal Close to Completion
- Oregon’s Psilocybin Program Faces Fee Hike
- Other Headlines
A Closer Look at Compass’ 6-Month Data and Commercial Plans
On Tuesday, we covered Compass Pathways’ readout covering 26-week data from its second Phase 3 study of COMP360 psilocybin for treatment-resistant depression (TRD): Compass Closes Out Phase 3 With 6-Month COMP006 Data, Eyes H1’27 Launch.
After our initial reporting published, the company shared more detailed slides (PDF) as well as prepared remarks on a webcast, which was followed by analyst Q&A with management.
Looking first at the slides shared on the webcast, we got a look at the performance of the 10 mg dose out to week 26...
Join Today
Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and research.
- Regular Bulletins featuring news, analysis, and research
- Articles and deep dives across psychedelic drug development, policy, and research
- Exclusive interviews with researchers, executives, and policymakers
- Bespoke resources and tools including the Psychedelic Bill Tracker
- Quarterly video briefings and slide decks
Already a member?
Sign In